Short Interest in Guardant Health, Inc. (NASDAQ:GH) Expands By 18.9%

Guardant Health, Inc. (NASDAQ:GHGet Rating) was the recipient of a large increase in short interest in December. As of December 30th, there was short interest totalling 5,100,000 shares, an increase of 18.9% from the December 15th total of 4,290,000 shares. Based on an average trading volume of 1,550,000 shares, the days-to-cover ratio is presently 3.3 days. Approximately 5.3% of the company’s stock are short sold.

Guardant Health Price Performance

NASDAQ GH opened at $31.70 on Friday. The company has a market cap of $3.25 billion, a PE ratio of -5.35 and a beta of 0.83. Guardant Health has a 52 week low of $24.63 and a 52 week high of $78.34. The company has a quick ratio of 6.10, a current ratio of 6.46 and a debt-to-equity ratio of 6.82. The firm’s 50-day simple moving average is $38.42 and its two-hundred day simple moving average is $46.50.

Guardant Health (NASDAQ:GHGet Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). The business had revenue of $117.40 million for the quarter, compared to analysts’ expectations of $118.18 million. Guardant Health had a negative net margin of 140.58% and a negative return on equity of 145.58%. Research analysts predict that Guardant Health will post -6.46 earnings per share for the current year.

Insider Transactions at Guardant Health

In other news, insider Kumud Kalia sold 3,125 shares of the company’s stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $51.87, for a total value of $162,093.75. Following the completion of the sale, the insider now owns 20,135 shares in the company, valued at approximately $1,044,402.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Xponance Inc. increased its position in shares of Guardant Health by 2.4% during the third quarter. Xponance Inc. now owns 11,639 shares of the company’s stock valued at $627,000 after buying an additional 269 shares during the period. Captrust Financial Advisors increased its position in shares of Guardant Health by 33.2% in the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after purchasing an additional 271 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Guardant Health by 4.9% in the second quarter. Commonwealth Equity Services LLC now owns 6,120 shares of the company’s stock worth $246,000 after purchasing an additional 286 shares during the last quarter. Manchester Capital Management LLC increased its position in shares of Guardant Health by 43.0% in the third quarter. Manchester Capital Management LLC now owns 965 shares of the company’s stock worth $52,000 after purchasing an additional 290 shares during the last quarter. Finally, Baird Financial Group Inc. increased its position in shares of Guardant Health by 2.1% in the third quarter. Baird Financial Group Inc. now owns 14,580 shares of the company’s stock worth $785,000 after purchasing an additional 296 shares during the last quarter. 90.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. The Goldman Sachs Group reduced their target price on shares of Guardant Health from $80.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, November 4th. Craig Hallum started coverage on shares of Guardant Health in a report on Wednesday, October 19th. They issued a “buy” rating and a $88.00 price target on the stock. JPMorgan Chase & Co. cut their price target on shares of Guardant Health from $100.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, November 18th. Cowen cut their price target on shares of Guardant Health from $110.00 to $83.00 in a report on Friday, November 4th. Finally, Stephens cut their price target on shares of Guardant Health from $99.00 to $90.00 and set an “overweight” rating on the stock in a report on Monday, November 7th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $90.39.

Guardant Health Company Profile

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Featured Articles

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.